Literature DB >> 19917631

Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer.

Leah C Pulling1, Marcie J Grimes, Leah A Damiani, Daniel E Juri, Kieu Do, Carmen S Tellez, Steven A Belinsky.   

Abstract

Death-associated protein kinase (DAPK), a mediator of apoptotic systems, is silenced by promoter hypermethylation in lung and breast tumors. This gene has a CpG island extending 2500 bp from the translational start site; however, studies characterizing its transcriptional regulation have not been conducted. Two transcripts for DAPK were identified that code for a single protein, while being regulated by two promoters. The previously identified DAPK transcript designated as exon 1 transcript was expressed at levels 3-fold greater than the alternate exon 1b transcript. Deletion constructs of promoter 1 identified a 332 bp region containing a functional CP2-binding site important for expression of the exon 1 transcript. While moderate reporter activity was seen in promoter 2, the region comprising intron 1 and containing a HNF3B-binding site sustained expression of the alternate transcript. Sequencing the DAPK CpG island in tumor cell lines revealed dense, but heterogenous methylation of CpGs that blocked access of the CP2 and HNF3B proteins that in turn, was associated with loss of transcription that was restored by treatment with 5-aza-2'-deoxycytidine. Prevalences were similar for methylation of promoter 1 and 2 and intron 1 in lung tumors, but significantly greater in promoter 2 and intron 1 in breast tumors, indicative of tissue-specific differences in silencing these two transcripts. These studies show for the first time dual promoter regulation of DAPK, a tumor suppressor gene silenced in many cancers, and substantiate the importance of screening for silencing of both transcripts in tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917631      PMCID: PMC2792322          DOI: 10.1093/carcin/bgp276

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  34 in total

1.  The first intron of the murine beta-casein gene contains a functional promoter.

Authors:  Andreas Kolb
Journal:  Biochem Biophys Res Commun       Date:  2003-07-11       Impact factor: 3.575

2.  Mitogenic stimulation of resting T cells causes rapid phosphorylation of the transcription factor LSF and increased DNA-binding activity.

Authors:  J L Volker; L E Rameh; Q Zhu; J DeCaprio; U Hansen
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

3.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

4.  Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype.

Authors:  Ulrich Lehmann; Gülhan Celikkaya; Britta Hasemeier; Florian Länger; Hans Kreipe
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  The first intron of the human osteopontin gene contains a C/EBP-beta-responsive enhancer.

Authors:  Francesca Giacopelli; Nadia Rosatto; Maria Teresa Divizia; Roberto Cusano; Gianluca Caridi; Roberto Ravazzolo
Journal:  Gene Expr       Date:  2003

6.  Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.

Authors:  Wen Yong Chen; Xiaobei Zeng; Mark G Carter; Craig N Morrell; Ray-Whay Chiu Yen; Manel Esteller; D Neil Watkins; James G Herman; Joseph L Mankowski; Stephen B Baylin
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

7.  Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Authors:  Essel Dulaimi; Jeanne Hillinck; Inmaculada Ibanez de Caceres; Tahseen Al-Saleem; Paul Cairns
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  Epigenetic down-regulation of death-associated protein kinase in lung cancers.

Authors:  Shinichi Toyooka; Kiyomi O Toyooka; Kuniharu Miyajima; Jyotsna L Reddy; Minoru Toyota; Ubradka G Sathyanarayana; Asha Padar; Melvyn S Tockman; Stephen Lam; Narayan Shivapurkar; Adi F Gazdar
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

9.  Death-associated protein kinase loss of expression is a new marker for breast cancer prognosis.

Authors:  Delphine Lévy; Geneviève Plu-Bureau; Yves Decroix; Danielle Hugol; William Rostène; Adi Kimchi; Anne Gompel
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

10.  Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death.

Authors:  L P Deiss; E Feinstein; H Berissi; O Cohen; A Kimchi
Journal:  Genes Dev       Date:  1995-01-01       Impact factor: 11.361

View more
  9 in total

1.  TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.

Authors:  Yang Yongbin; Li Jinghua; Zhao Zhanxue; Zang Aimin; Jia Youchao; Shang Yanhong; Jiao Manjing
Journal:  Tumour Biol       Date:  2014-08-15

2.  FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones.

Authors:  Ioannis G Koutlas; Damon R Olson; Jawhar Rawwas
Journal:  Head Neck Pathol       Date:  2020-06-05

3.  Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.

Authors:  Athanassios Kyrgidis; Thrasivoulos-George Tzellos; Stefanos Triaridis
Journal:  J Carcinog       Date:  2010-04-01

4.  Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.

Authors:  Ying Li; Min Zhu; Xiaoju Zhang; Dongjun Cheng; Xitao Ma
Journal:  Drug Des Devel Ther       Date:  2015-03-24       Impact factor: 4.162

5.  Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome.

Authors:  Annette M Lim; Ida Lm Candiloro; Nicholas Wong; Marnie Collins; Hongdo Do; Elena A Takano; Christopher Angel; Richard J Young; June Corry; David Wiesenfeld; Stephen Kleid; Elizabeth Sigston; Bernard Lyons; Danny Rischin; Benjamin Solomon; Alexander Dobrovic
Journal:  Clin Epigenetics       Date:  2014-12-09       Impact factor: 6.551

Review 6.  Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

Review 7.  Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease.

Authors:  Dongmei Chen; Xiao Z Zhou; Tae H Lee
Journal:  Recent Pat Anticancer Drug Discov       Date:  2019       Impact factor: 4.169

8.  DNA methylation and apoptosis resistance in cancer cells.

Authors:  Eric Hervouet; Mathilde Cheray; François Marie Vallette; Pierre-François Cartron
Journal:  Cells       Date:  2013-07-18       Impact factor: 6.600

9.  Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference.

Authors:  Mélodie Grandin; Pauline Mathot; Guillaume Devailly; Yannick Bidet; Akram Ghantous; Clementine Favrot; Benjamin Gibert; Nicolas Gadot; Isabelle Puisieux; Zdenko Herceg; Jean-Guy Delcros; Agnès Bernet; Patrick Mehlen; Robert Dante
Journal:  EMBO Mol Med       Date:  2016-08-01       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.